Literature DB >> 10451159

Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT).

S A Halperin1, E E Wang, B Law, E Mills, R Morris, P Déry, M Lebel, N MacDonald, T Jadavji, W Vaudry, D Scheifele, G Delage, P Duclos.   

Abstract

To assess the morbidity associated with the continued high levels of pertussis, we studied all children <2 years of age who were admitted to the 11 Immunization Monitoring Program--Active (IMPACT) centers, which constitute 85% of Canada's tertiary care pediatric beds. In the 7 years preceding implementation of acellular pertussis vaccine, a total of 1,082 pertussis cases were reported, of which 49.1% were culture-confirmed. The median age of the patients was 12.4 weeks; 78.9% of cases were in children <6 months of age. Complications of pertussis were common: pneumonia was reported in 9.4% of cases, new seizures in 2.3%, and encephalopathy in 0.5%. There were 10 deaths (0.9%), all in children < or =6 months of age. Duration of hospitalization was longer (9.3 days vs. 4.9 days; P = .001) and intensive care was required more frequently (19.2% vs. 4.9%; P = .001) in infants under <6 months of age than in those > or =6 months. Pertussis continues to cause significant morbidity and occasional mortality in Canada, particularly in young infants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10451159     DOI: 10.1086/514792

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Maternal immunity provides protection against pertussis in newborn piglets.

Authors:  Shokrollah Elahi; Rachelle M Buchanan; Lorne A Babiuk; Volker Gerdts
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Pertussis control in Canada.

Authors:  Scott A Halperin
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

3.  Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.

Authors:  Michael Iskedjian; John H Walker; Gaston De Serres; Thomas R Einarson
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 4.  Diagnosis and management of pertussis.

Authors:  Alberto E Tozzi; Lucia Pastore Celentano; Marta Luisa Ciofi degli Atti; Stefania Salmaso
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

5.  Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project.

Authors:  David W Scheifele; Scott A Halperin; Ronald Gold; Heather Samson; Arlene King
Journal:  Paediatr Child Health       Date:  2002-11       Impact factor: 2.253

6.  Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What Canadian health care providers know and need to know.

Authors:  D MacDougall; B A Halperin; D MacKinnon-Cameron; L Li; S A McNeil; J M Langley; S A Halperin
Journal:  Hum Vaccin Immunother       Date:  2015-06-19       Impact factor: 3.452

7.  Shift in the epidemiology of pertussis infection: an indication for pertussis vaccine boosters for adults?

Authors:  Sylvia H Yeh; ChrisAnna M Mink
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.

Authors:  Caroline Roduit; Paola Bozzotti; Nathalie Mielcarek; Paul-Henri Lambert; Giuseppe del Giudice; Camille Locht; Claire-Anne Siegrist
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

9.  Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects.

Authors:  Laurent Coudeville; Annelies Van Rie; Denis Getsios; J Jaime Caro; Pascal Crépey; Van Hung Nguyen
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

10.  Infantile pertussis rediscovered in China.

Authors:  Jingmin Wang; Yonghong Yang; Jie Li; Jussi Mertsola; Heikki Arvilommi; Xuzhuang Shen; Qiushui He
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.